DWP14012 20mg

DRUG3 trials

Sponsors

Daewoong Pharmaceutical Co. LTD.

Conditions

Healed Erosive EsophagitisNon-Erosive Esophageal Reflux DiseaseNon-Erosive Gastro-Esophageal Reflux DiseaseNon-erosive Reflux DiseasePeptic Ulcer

Phase 3

Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer

CompletedNCT04784910

Daewoong Pharmaceutical Co. LTD.Peptic Ulcer

Start: 2021-05-21End: 2023-12-11Updated: 2024-07-08

Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non-Erosive Gastroesophageal Reflux Disease (NERD)

Daewoong Pharmaceutical Co. LTD.Non-erosive Reflux Disease, Non-Erosive Gastro-Esophageal Reflux Disease, Non-Erosive Esophageal Reflux Disease

Start: 2023-08-31End: 2025-03-31Target: 324Updated: 2023-11-08

Efficacy and Safety of DWP14012 for Long-Term Maintenance Therapy in Patients With Healed Erosive Esophagitis

Not yet recruitingNCT07746518

Daewoong Pharmaceutical Co. LTD.Healed Erosive Esophagitis

Start: 2026-09-01End: 2030-03-01Target: 420Updated: 2026-08-13

Related Papers

Comparing the Efficacy and Safety of Fexuprazan and Lansoprazole for the Prevention of Nonsteroidal Anti-inflammatory Drug-Induced Peptic Ulcer

Gut and Liver2025-06-262 citations